The influence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma: Correlation of results from hematoxylin and eosin staining with results from immunostaining for factor VIII-related antigen

Cancer

Volumn 82, Issue 4, 1998, Pages 689-696

  Obermair, Andreas ^a   Wanner, Christian ^a   Bilgi, Selcuk ^a   Speiser, Paul ^a   Reisenberger, Klaus ^a   Kaider, Alexandra ^b   Kainz, Christian ^a   Leodolter, Sepp ^a   Breitenecker, Gerhard ^a   Gitsch, Gerald ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blood vessel invasion; Cervical carcinoma; Gynecologic oncology; Lymphatic vessel invasion; Prognostic factors; Vascular space involvement

Indexed keywords

BLOOD CLOTTING FACTOR 8; EOSIN; HEMATOXYLIN;

ANALYTIC METHOD; ARTICLE; CANCER INVASION; CANCER STAGING; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ENDOTHELIUM, VASCULAR; EOSINE YELLOWISH-(YS); FEMALE; FOLLOW-UP STUDIES; HEMATOXYLIN; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STAINING AND LABELING; UTERINE CERVICAL NEOPLASMS; VON WILLEBRAND FACTOR;

EID: 18844478396     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980215)82:4<689::AID-CNCR11>3.0.CO;2-U     Document Type: Article

References (28)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45:8-30 [Erratum, CA Cancer J Clin 1995; 45:127-8].
2. Pettersson F. Annual report on the results of treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics, 1994.
3. Cannistra SA, Niloff JM. Cancer of the uterine cervix. New Engl J Med 1996; 334:1030-8.
4. Hatch KD. Cervical cancer. In: Berek JS, Hacker NF, editors. Practical gynecologic oncology. Baltimore: Williams and Wilkins, 1994:243-83.
5. Perez CA, Kurman RJ, Stehman FB, Thigpen JT. Uterine cervix. In: Hoskins WJ, Perez CA, Young RC. Principles and practice of gynecologic oncology. Philadelphia: J. B. Lippincott, 1993:591-662.
6. Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, et al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995; 76 (Suppl 10):1978-86.
7. Werner-Wasik M, Schmid CH, Bornstein L, Ball HG, Smith DM, Madoc-Jones H. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32:1309-17.
8. Van Nagell JR, Greenwell N, Powell DF, Donaldson ES, Hanson MB, Gay EC. Microinvasive carcinoma of the cervix. Am J Obstet Gynecol 1983; 145:981-91.
9. Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL Jr. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986; 57:1584-93.
10. Gonzalez-Gonzalez D, Ketting BW, van-Bunningen B, van-Dijk JD. Carcinoma of the uterine cervix stage IB and UA: results of postoperative irradiation in patients with microscopic infiltration in the parametrium and/or lymph node metastasis. Int J Radiat Oncol Biol Phys 1989; 16:389-95.
11. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 38:352-7.
12. Kainz C, Gitsch G, Tempfer C, Heinzl H, Koelbl H, Breitenecker G, et al. Vascular space invasion and inflammatory stromal reaction as prognostic factors in patients with surgically treated cervical cancer stage IB to IIB. Anticancer Res 1994; 14:2245-8.
13. Mathews CM, Burke TW, Tornos C, Eifel PJ, Atkinson EN, Stringer CA, et al. Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients. Gynecol Oncol 1993; 49:19-23.
14. Fuller AF, Elliott N, Kosloff C, Hoskins WJ, Lewis JL. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 1989; 33:34-9.
15. Lee AK. Basement membrane and endothelial agents: their role in evaluation of tumor invasion and metastasis. In: De-Lellis RA, editor. Advances in immunohistochemistry. New York: Raven Press, 1988:363-93.
16. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993; 10: 302-13.
17. Broders AC. Squamous-cell epithelioma of the lip: a study of five hundred and thirty-seven cases. JAMA 1920; 74: 656-64.
18. Obermair A, Kohlberger P, Bancher-Todesca D, Tempfer C, Sliutz G, Leodolter S, et al. Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 1996; 63:204-9.
19. Roche WO, Norris HC. Microinvasive carcinoma of the cervix. Cancer 1975; 36:180-6.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985; 53:457-81.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-70.
22. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34:187-220.
23. McLellan R, Dillon MB, Woodruff ID, Heatley GJ, Fields AL, Rosenshein NB. Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery. Gynecol Oncol 1994; 52:253-9.
24. Smiley LM, Burke TW, Silva EG, Morris M, Gershenson DM, Wharton JT. Prognostic factors in stage IB squamous cervical cancer patients with low risk for recurrence. Obstet Gynecol 1991; 77:271-5.
25. Wiggins DL, Granai GO, Steinhoff MM, Calabresi P. Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 1995; 56:353-6.
26. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51:6180-4.
27. School DD, Obando A, Cusack JC, Goedegebuure PS, Brem H. The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int J Cancer 1993; 55:630-5.
28. Malfetano J, Teng N, Rasmussen D. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary: a dose finding study [Abstract 764]. Proc Am Soc Clin Oncol 1996; 15:283.